Results 71 to 80 of about 55,457 (267)

Treatment patterns and cost estimations of systemic chemotherapy for pancreatic cancer in Japan: A retrospective database study

Cancer Medicine, 2023
Background This study aimed to clarify the treatment patterns of pancreatic cancer patients receiving systemic chemotherapy in Japan and to estimate the direct medical costs in actual practice.
Yuki Takumoto, Ryotaro Shibahara, Hajime Asami, Manabu Akazawa   +3 more
doaj   +1 more source

Heat Shock Protein 90: From Molecular Chaperone Function to Therapeutic Targeting in Malignancies

Advanced Science, EarlyView.
In this review, an integrated conceptual framework linking HSP90's molecular chaperone functions to its pathological roles in cancer is proposed. HSP90 serves as a central node that integrates oncogenic signaling, buffers proteotoxic stress, maintains cancer stem cell plasticity, and shapes tumor‐immune interactions, all of which converge to drive ...
Beibei Zhang, Xinxin Zou, Jiansong Zhou, Qinmiao Sun, Dahua Chen   +4 more
wiley   +1 more source

Efficacy and immunogenic effects of Tumor Treating Fields (TTFields) in preclinical models of pancreatic ductal adenocarcinoma, with and without gemcitabine/nab-paclitaxel. [PDF]

Int J Cancer
What's new? Adaptive immune responses are typically limited in pancreatic ductal adenocarcinoma, resulting in minimal efficacy of immune checkpoint inhibitors. Tumor Treating Fields (TTFields) therapy, which uses low‐intensity intermediate‐frequency electric fields to disrupt cancer cell processes, has been approved for certain cancers.
Kan T, Haj Khalil T, Barsheshet Y, Voloshin T, Koren L, Koltun B, David C, Wainer-Katsir K, Vorontsova A, Brant B, Zisman-Rozen S, Ene HM, Frechtel-Gerzi R, Cahal S, Klein-Goldberg A, Lifshitz L, Zemer Tov E, Shai M, Haber A, Giladi M, Weinberg U, Palti Y.   +21 more
europepmc   +2 more sources

FOS3D: A Fluorescence‐Enabled Toolkit for Characterizing a Three‐dimensional Osteosarcoma Model

Advanced Science, EarlyView.
FOS3D describes fluorescent (F) osteosarcoma (OS) cells in a tri‐dimensional (3D) model. The study comprises three phases: development, where biofabrication parameters are tuned to achieve cytocompatibility and tumor‐specific mechanical properties in cell‐laden gelatin methacryloyl constructs; validation, where whole‐well fluorescence reading is ...
William Humble, Wiktor Zywicki, Enrico Lucarelli, Ania Naila Guerrieri, Francesca Taraballi, Gianluca Cidonio, Claudia Di Bella, Carmine Onofrillo, Andrea J. O'Connor, Serena Duchi   +9 more
wiley   +1 more source

Verbessert nab-Paclitaxel die Melanom-Chemotherapie? [PDF]

Im Focus Onkologie, 2016
Trotz den Fortschritten in der Immuntherapie spielt die Chemotherapie beim metastasierten Melanom nach wie vor eine wichtige Rolle. Dies zeigt sich in einer aktuellen Phase-III-Studie, in der an Albumin-Nanopartikel gebundenes Paclitaxel (nab-Paclitaxel) mit Dacarbazin verglichen wurde.
Barbara Kreutzkamp, Carola Berking
openaire   +1 more source

A Biomimetic Dual‐Targeting Nano‐APA‐Editor Reprograms the 3'UTR Landscape for Tongue Squamous Cell Carcinoma Therapy

Advanced Science, EarlyView.
This study unveils a pathogenic axis in oral cancer where NUDT21 suppresses a tumor suppressor network, prominently PTEN, via 3'UTR lengthening. To exploit this transcriptomic vulnerability, we developed a biomimetic Nano‐APA‐editor. By delivering CRISPR/Cas9, we reprogrammed the global 3'UTR landscape, restoring multi‐target tumor suppression and ...
Yiran Ao, Bin Gu, Hui Zhao, Kun Tan, Qin Zhao, Zhengjun Shang   +5 more
wiley   +1 more source

Efficacy and safety of nab-paclitaxel in metastatic gastric cancer: a meta-analysis - supplementary files

, 2023
Background: Nab-paclitaxel is formulated to address several limitations of paclitaxel. Methods: A systematic review was done of several databases and a meta-analysis with a random-effects model was conducted to assess the efficacy and safety of nab ...
Ali Mussa (17418071), Suhana Ahmad (13986925), Lidawani Lambuk (17418068), Vincent Tee (13863965), Naveed Ahmed (2433958), Nur Fazimah Sahran (17418076), Ros Akmal Mohd Idris (17418073), Rosline Hassan (8293071), Yean Yean Chan (17418079), Yeong Yeh Lee (464368), Rohimah Mohamud (5465972)   +10 more
core   +1 more source

Preoperative Gemcitabine/Nab‐Paclitaxel With Concurrent Radiation Therapy for Borderline Resectable Pancreatic Cancer: A Comparative Analysis With Preoperative Chemoradiation Therapy Using Gemcitabine Alone

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background Although NCCN guidelines recommend preoperative therapy for borderline resectable pancreatic cancer (BR‐PC), it is still unclear which regimen is better. The study objective was to elucidate the prognostic significance of neoadjuvant chemoradiotherapy (NACRT) with gemcitabine/nab‐paclitaxel (GnP‐RT) compared to gemcitabine alone ...
Hirofumi Akita, Hidenori Takahashi, Yousuke Mukai, Masahiko Kubo, Shinichiro Hasegawa, Masayoshi Yasui, Takeshi Omori, Hiroshi Miyata, Hiroshi Wada, Kunihito Gotoh   +9 more
wiley   +1 more source

Reinitiating nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer.

, 2014
381 Background: The recent results of the phase III trial MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) demonstrated an improvement in progression free survival, overall response rate, and overall survival for the combination of nab ...
Daniel D. Von Hoff, Ramesh K. Ramanathan, Gayle S. Jameson, Katy Schroeder, Erkut Borazanci   +4 more
core   +1 more source

Essential Updates 2024–2025: Surgical Strategy for Esophageal Cancer Toward a New Paradigm in the Era of Immunotherapy and Personalization

Annals of Gastroenterological Surgery, EarlyView.
This review summarizes key advances from 2024 to 2025 that are reshaping esophageal cancer surgery toward a strategy‐oriented, personalized paradigm through the integration of immunotherapy, population aging, and intelligent technologies. Adjuvant nivolumab after neoadjuvant chemoradiotherapy remains the only perioperative approach with durable benefit,
Shuichiro Oya, Koichi Yagi, Yoshifumi Baba   +2 more
wiley   +1 more source